More Stories

Informist, Wednesday, Dec. 10, 2025

 

--Sun Pharma:Won't sell semaglutide in India till Novo Nordisk has patent 

--CONTEXT: Novo Nordisk moved HC to bar Sun Pharma from selling semaglutide 

--Sun Pharma: To export semaglutide where Novo Nordisk doesn't have patent 

 

NEW DELHI – The Delhi High Court Wednesday noted an undertaking from Sun Pharmaceutical Industries Ltd. that it will manufacture its version of diabetes and obesity drug 'Semaglutide' for exporting to countries where Novo Nordisk AS has not been granted a patent for the drug. Further, the court noted that Sun Pharmaceutical will not sell its version of the Semaglutide drug in India till March 2026, when Novo Nordisk's patent for the drug will expire.

 

The court asked Sun Pharmaceutical to file an affidavit with respect to the undertakings given by them. It registered Novo Nordisk's plea seeking to bar Sun Pharmaceutical from manufacturing and selling its version of Semaglutide as a suit and issued summons to the latter.

 

At the outset, Sun Pharmaceutical said it was aware of the high court's judgment on Dec. 2 and it would give undertakings similar to those of Dr. Reddy's Laboratories Ltd. and its contract manufacturer OneSource Speciality Pharma Ltd. on Novo Nordisk's plea regarding Semaglutide. The court said if the parties appeal against the Dec. 2 judgment, then Sun Pharmaceutical will change its undertaking based on any variation to the original order. 

 

Rejecting Novo Nordisk's plea for an interim injunction, the Delhi High Court on Dec. 2 had allowed Dr. Reddy's Laboratories and OneSource Speciality to manufacture their version of diabetes and obesity drug 'semaglutide' and export the same to countries where Novo Nordisk does not have a patent. However, it said Dr. Reddy's Laboratories and OneSource Speciality will not sell their version of Semaglutide drug in India till the expiry of Novo Nordisk's patent in March 2026. 

 

Justice Manmeet Pritam Singh Arora had said there was a credible challenge to the validity of Novo Nordisk's patent on Semaglutide drug. Currently, Novo Nordisk sells 'Wegovy' and 'Rybelsus' brands using its patent on Semaglutide and also recently received the Central Drugs Standard Control Organisation's approval for Ozempic drug. The Danish drugmaker held a primary consumption patent for Semaglutide, which expired in September 2024. However, Novo Nordisk still held the secondary patent in India relating to the manufacturing process and delivery mechanism of Semaglutide, which remained valid till March 2026. 

 

At 1220 IST, shares of Sun Pharmaceutical Industries were up 0.1% at INR 1,777.50 on the National Stock Exchange.  End

 

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Reported by Surya Tripathi

Edited by Tanima Banerjee

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2025. All rights reserved.